3-Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans

被引：27

作者：

Dylag, Mariusz ^{[1
]}

Lis, Pawel ^{[1
]}

Niedwiecka, Katarzyna ^{[1
]}

Ko, Young H. ^{[2
]}

Pedersen, Peter L. ^{[3
]}

Goffeau, Andre ^{[4
]}

Ulaszewski, Stanislaw ^{[1
]}

机构：

[1] Univ Wroclaw, Inst Genet & Microbiol, PL-51148 Wroclaw, Poland

[2] KoDiscovery LLC, Baltimore, MD 21201 USA

[3] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA

[4] Catholic Univ Louvain, Inst Sci Vie, B-1348 Louvain, Belgium

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2013年 / 434卷 / 02期

关键词：

3-Bromopyruvate; Antifungal activity; Cryptococcus neoformans; MULTIDRUG-RESISTANCE PROTEINS; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; GLUTATHIONE; FUNGI; YEAST; TRANSPORTERS; FLUCYTOSINE; MENINGITIS; TOXICITY;

D O I：

10.1016/j.bbrc.2013.02.125

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We have investigated the antifungal activity of the pyruvic acid analogue: 3-bromopyruvate (3-BP). Growth inhibition by 3-BP of 110 strains of yeast-like and filamentous fungi was tested by standard spot tests or microdilution method. The human pathogen Cryptococcus neoformans exhibited a low Minimal Inhibitory Concentration (MIC) of 0.12-0.15 mM 3-BP. The high toxicity of 3-BP toward C neoformans correlated with high intracellular accumulation of 3-BP and also with low levels of intracellular ATP and glutathione. Weak cytotoxicity towards mammalian cells and lack of resistance conferred by the PDR (Pleiotropic Drug Resistance) network in the yeast Saccharomyces cerevisiae, are other properties of 3-BP that makes it a novel promising anticryptococcal drug. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：322 / 327

页数：6

共 34 条

[1] Amberg DC, 2005, Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual
[2] [Anonymous], M27A2 NCCLS
[3] Cerebrospinal fluid lactate and pyruvate concentrations and their ratio in children: Age-related reference intervals
Benoist, JF
Alberti, C
Leclercq, S
Rigal, O
Jean-Louis, R
de Baulny, HO
Porquet, D
Biou, D
[J]. CLINICAL CHEMISTRY, 2003, 49 (03) : 487 - 494
[4] Treatment of invasive fungal infections in cancer patients-Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Boehme, Angelika
Ruhnke, Markus
Buchheidt, Dieter
Cornely, Oliver A.
Einsele, Herrmann
Enzensberger, Ruxandra
Hebart, Holger
Heinz, Werner
Junghanss, Christian
Karthaus, Meinolf
Kruger, William
Krug, Utz
Kubin, Thomas
Penack, Olaf
Reichert, Dietmar
Reuter, Stefan
Silling, Gerda
Sudhoff, Thomas
Ullmann, Andrew J.
Maschmeyer, Georg
[J]. ANNALS OF HEMATOLOGY, 2009, 88 (02) : CP6 - 110
[5] Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer
Buijs, Manon
Vossen, Josephina A.
Geschwind, Jean-Francois H.
Ishimori, Takayoshi
Engles, James M.
Acha-Ngwodo, Obele
Wahl, Richard L.
Vali, Mustafa
[J]. INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 120 - 123
[6] Efflux-Mediated Antifungal Drug Resistance
Cannon, Richard D.
Lamping, Erwin
Holmes, Ann R.
Niimi, Kyoko
Baret, Philippe V.
Keniya, Mikhail V.
Tanabe, Koichi
Niimi, Masakazu
Goffeau, Andre
Monk, Brian C.
[J]. CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (02) : 291 - +
[7] The lactate-proton symport of Saccharomyces cerevisiae is encoded by JEN1
Casal, M
Paiva, S
Andrade, RP
Gancedo, C
Leao, C
[J]. JOURNAL OF BACTERIOLOGY, 1999, 181 (08) : 2620 - 2623
[8] Transport of carboxylic acids in yeasts
Casal, Margarida
Paiva, Sandra
Queiros, Odilia
Soares-Silva, Isabel
[J]. FEMS MICROBIOLOGY REVIEWS, 2008, 32 (06) : 974 - 994
[9] Ten Challenges on Cryptococcus and Cryptococcosis
Del Poeta, Maurizio
Casadevall, Arturo
[J]. MYCOPATHOLOGIA, 2012, 173 (5-6) : 303 - 310
[10] Drug resistance - The fight against fungi
Goffeau, Andre
[J]. NATURE, 2008, 452 (7187) : 541 - 542

← 1 2 3 4 →